Effects of casein glycomacropeptide on the early development of primary colorectal cancer in rats

In this paper,we utilized dimethylhydrazine(DMH)-induced colorectal cancer(CC)model rats to explore the effects of casein glycomacropeptide(CGMP)on colorectal cancer.Rats with CC were orally administrated with 10,50,or 100 mg/kg bw d CGMP,or the same volume of phosphatebuffered saline for 15 weeks.The total numbers of aberrant crypt foci(ACF)and crypts per focus in colon were scored using a light microscope at low magnification after the colon was stained with methylene blue solutions.The methylation level of DNA extracted from colon was detected using methylation-specific PCR.The expression of p16 and mucin 2(MUC2)proteins were measured by immunohistochemistry.The results showed that although ACF were found in rats treated with CGMP,their number was significantly decreased compared to that of model rats.In addition,methylation and expression levels of p16 and MUC2 were also inhibited by CGMP,which were more obvious in rats treated with 50 mg/kg bw d CGMP.In conclusion,CGMP has potential application as nutritional therapy for preventing colorectal cancer.©2013 Beijing Academy of Food Sciences.Production and hosting by Elsevier B.V.All rights reserved.

Effects of casein glycomacropeptide supplementation on growth performance,intestinal morphology, intestinal barrier permeability and inflammatory responses in Escherichia coli K88 challenged piglets

Casein glycomacropeptide(CGMP) is a bioactive peptide derived from milk with multiple functions. This study was aimed at evaluating the effects of CGMP as a potential feed additive on growth performance,intestinal morphology, intestinal barrier permeability and inflammatory responses of Escherichia coli K88(E. coli K88) challenged piglets. Eighteen weaning piglets were randomly assigned to three groups.Control group and K88 challenged group received a basal diet, and CGMP treated group received the basal diet supplemented with 1% of CGMP powder. The trail lasted for 12 days, K88 was orally administered to the piglets of K88 challenged group and CGMP treated group on days 8-10. The results showed that the diet containing 1% CGMP significantly alleviated the decrease in average daily gain(P <0.05),increase in pathogenic bacteria amounts in intestinal contents(P < 0.05), intestinal morphology(P > 0.05) and barrier permeability damage(P < 0.05), and acute inflammatory response(P < 0.05)induced by E. coli K88 infection. In conclusion, CGMP supplementation in the diet protected the weaning piglets against E. coli K88 infection.